How many drugs treat Allergic rhinitis?

Drug Landscape tracks 10 marketed treatments for Allergic rhinitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/allergic-rhinitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Allergic rhinitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allergic rhinitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Allergic rhinitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Arnuity Ellipta	FLUTICASONE FUROATE	Haleon Us Holdings	Corticosteroid	Glucocorticoid receptor	2007-01-01
Xyzal	LEVOCETIRIZINE	Sanofi	Histamine-1 Receptor Antagonist	Histamine H1 receptor	2007-01-01
Omnaris	CICLESONIDE	Covis	ciclesonide	Glucocorticoid receptor	2006-01-01
Omnaris	Alvesco	Takeda Gmbh	ciclesonide	Glucocorticoid receptor	2006-01-01
Clarinex	desloratadine	Generic (originally Schering-Plough/MSD)	Histamine-1 Receptor Antagonist [EPC]	5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1	2001-12-21
Rupax	RUPATADINE	Teikoku Seiyaku	rupatadine	Histamine H1 receptor	2001-01-01
Propadrine	PHENYLPROPANOLAMINE	Alpharma Us Pharms	Indirectly Acting Sympathomimetic Amines	Sodium-dependent noradrenaline transporter	2000-01-01
Singulair	montelukast	Merck & Co.	Leukotriene receptor antagonist (LTRA)	Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	1998-02-20
Mizollen	MIZOLASTINE	Sanofi	mizolastine	Histamine H1 receptor	1998-01-01
Allegra	fexofenadine	Generic (originally Hoechst Marion Roussel/Sanofi)	Second-generation antihistamine	Solute carrier organic anion transporter family member 1A2, Multidrug resistance protein 1, Histamine H1 receptor	1996-07-25

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 32 drugs in Allergic rhinitis
Generic (multiple manufacturers) · 4 drugs in Allergic rhinitis
Pfizer · 4 drugs in Allergic rhinitis
Merck & Co. · 3 drugs in Allergic rhinitis
Novartis · 3 drugs in Allergic rhinitis
Bayer · 3 drugs in Allergic rhinitis
Sanofi · 2 drugs in Allergic rhinitis
Generic (originally Schering) · 2 drugs in Allergic rhinitis
GSK · 2 drugs in Allergic rhinitis
Baxter · 1 drug in Allergic rhinitis
Covis · 1 drug in Allergic rhinitis
Auxilium Pharms Inc · 1 drug in Allergic rhinitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Allergic rhinitis:

Cite this brief

Drug Landscape (2026). Allergic rhinitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/allergic-rhinitis. Accessed 2026-06-10.

Allergic rhinitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing